Canterbury, Australia

Robert Charles Atkins

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Charles Atkins. Retrieved from https://idiyas.com/inventor/robert-charles-atkins

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,659 
Other
 patents

Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Robert Charles Atkins

Introduction:

Roberts Charles Atkins, a prolific inventor based in Canterbury, Victoria 3126, AU, has made significant contributions in the field of biopharmaceuticals with a focus on diabetic nephropathy treatment.

Latest Patents:

Atkins holds a groundbreaking patent titled "Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy." This invention revolves around the use of N-phenyl-2-pyrim-idine-amine derivatives in the manufacture of pharmaceutical compositions for diabetic nephropathy treatment.

Career Highlights:

With a notable career trajectory, Atkins has showcased his expertise in developing novel solutions for complex medical conditions. His patent exemplifies his commitment to advancing therapeutic interventions for diabetic nephropathy.

Collaborations:

Atkins has collaborated with esteemed professionals in the field, including Steven James Chadban and Mark Emmanuel Cooper. Together, they have synergized their knowledge and skills to drive innovation in the realm of biopharmaceuticals.

Conclusion:

Robert Charles Atkins stands out as a pioneering inventor with a relentless passion for leveraging scientific advancements to enhance healthcare outcomes. His patent underscores his dedication to creating impactful solutions for challenging medical conditions, leaving a lasting legacy in the realm of biopharmaceutical innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…